Henry Schein (HSIC) vs Oscar Health (OSCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oscar Health (OSCR) has outperformed Henry Schein (HSIC) over the past year, gaining 46.5% versus a gain of 28.9%. Over five years, OSCR leads with a +107.6% price change compared with +8.0% for HSIC. Oscar Health is the larger company by market cap ($10.22 billion vs $9.43 billion), about 1.1 times the size.
On valuation, Henry Schein trades at a lower forward P/E (14.1x vs 15.3x for Oscar Health). Henry Schein converts more of its revenue into profit, with a net margin of 3.0% versus -3.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HSIC | OSCR |
|---|---|---|
| Share price | $84.63 | $33.10 |
| Market cap | $9.43B | $10.22B |
| 1-day change | +1.16% | +0.58% |
| YTD return | +10.69% | +129.02% |
| 1-year return | +28.95% | +46.46% |
| 5-year return | +8.03% | +107.63% |
| P/E ratio (TTM) | 24.67 | 25.66 |
| Forward P/E | 14.14 | 15.29 |
| EPS (TTM) | $3.43 | $1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.18B | $11.70B |
| Revenue growth (YoY) | +4.03% | +27.50% |
| Net income (latest FY) | $398.00M | $-443.15M |
| Gross margin | 31.14% | — |
| Operating margin | 4.95% | -3.39% |
| Net margin | 3.02% | -3.79% |
| 52-week high | $92.18 | $34.48 |
| 52-week low | $61.95 | $10.69 |
| Distance from 52-week high | -8.19% | -4.00% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +14.94% | +6.95% |
| Average volume | 1.20M | 5.18M |
| Shares outstanding | 111.45M | 273.47M |
| Employees | 25,000 | 2,305 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSCR has outperformed HSIC by 17.5 percentage points over the past year.
- Henry Schein is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -3.8 cents for Oscar Health.
- Oscar Health grew revenue faster in its latest fiscal year (+27.50% vs +4.03%).
About Henry Schein
HSIC stock →Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Health Care · Medical Specialities · 25,000 employees
About Oscar Health
OSCR stock →Oscar Health, Inc. operates as a healthcare technology company in the United States.
Health Care · Medical Specialities · 2,305 employees
HSIC vs OSCR FAQ
Which is bigger, Henry Schein or Oscar Health?
Oscar Health (OSCR) is larger, with a market capitalization of $10.22B compared with $9.43B for Henry Schein (HSIC).
Which stock has performed better over the past year, HSIC or OSCR?
OSCR returned +46.46% over the past 12 months, compared with +28.95% for HSIC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HSIC or OSCR?
HSIC has the lower trailing P/E at 24.7, versus 25.7 for OSCR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Henry Schein and Oscar Health in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.